EYPT EyePoint Pharmaceuticals Inc.

1.86
+0.01  (+0%)
Previous Close 1.85
Open 1.85
Price To Book 6.87
Market Cap 197,182,404
Shares 106,297,792
Volume 48,314
Short Ratio
Av. Daily Volume 309,215

NewsSee all news

  1. EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting

    WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema
FDA approval announced October 15, 2018.
YUTIQ
Non-infectious uveitis
sNDA filing due 2019 for 6-month formulation.
Yutiq
Non-infectious uveitis

Latest News

  1. EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting

    WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today